Why ImmunityBio stock jumped nearly 40%: ANKTIVA sales surge and a fresh trial timeline
New York, Jan 18, 2026, 07:03 (EST) — Market closed ImmunityBio’s IBRX shares ended Friday at $5.52, jumping roughly 40% following a series of company updates that attracted momentum traders. Trading volume surged past 182 million shares. This shift is key as ImmunityBio heads into a shortened week, aiming to convert early interest in its first cancer drug into consistent revenue. Investors also received fresh insight on the company’s timeline for expanding ANKTIVA into a wider first-line bladder cancer market. ImmunityBio reported preliminary net product revenue of roughly $113 million for 2025 in a Friday release, with fourth-quarter revenue hitting